Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

943
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
943
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

313
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
313
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

350
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
350
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

823
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
823

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026
Same author

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Brain : a journal of neurology·2026
Same author

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

bioRxiv : the preprint server for biology·2026
Same author

Long-Term Outcomes in Stiff Person Spectrum Disorder.

European journal of neurology·2026
Same author

Novel methods for neural IgG characterization and validation in autoimmune neurologic disorders.

Journal of immunological methods·2026
Same author

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice.

Annals of clinical and translational neurology·2026

相关实验视频

Updated: Jun 30, 2025

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.4K

副发性运动障碍 副发性运动障碍

Andrew McKeon1, Jennifer Tracy2

  • 1Department of Neurology, Mayo Clinic, Rochester, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.

Handbook of clinical neurology
|March 17, 2024
PubMed
概括

副发性运动障碍是与癌症相关的自身免疫性疾病,呈现出各种神经系统症状. 识别特定的自身抗体有助于诊断,预测疾病的进展,并指导治疗以获得更好的患者结果.

科学领域:

  • 神经学 神经学
  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学

背景情况:

  • 副发性运动障碍是与全身癌症相关的自身免疫神经系统疾病.
  • 这些疾病表现为各种运动异常,包括动力衰竭,低动力和高动力,有时模仿神经退行性疾病.

研究的目的:

  • 突出瘤性自身抗体在区分癌症关联,病程和治疗反应方面的诊断效用.
  • 强调基于血清和脑脊液 (CSF) 的个人资料查方法.

主要方法:

  • 对瘤性运动障碍的临床表现和诊断标记的审查.
  • 分析抗体生物标志物,样品类型 (血清/CSF),神经表现,癌症关联和治疗结果.
  • 讨论免疫疗法选择,包括皮质类固醇,IVIg,血交换,rituximab和环胺.

主要成果:

  • 自身抗体概况,如卵巢癌中的抗Yo抗体或霍奇金淋巴瘤中的抗甲基酸盐受体1抗体,与特定的临床表型和预后相关.
  • 亚急性发作和非经典特征有助于区分这些疾病与神经退行性疾病.
  • 越来越多的抗体生物标志物清单需要一个全面的查策略.

结论:

  • 早期和准确的诊断副瘤运动障碍对于有效的管理至关重要.
关键词:
抗体是对抗体的一种.过敏症 过敏症 过敏症 过敏症科雷亚 科雷亚 科雷亚运动 运动 运动肌肉细胞结质 (myoclonus) 是一个细胞结质.帕拉尼诺普拉斯蒂克是一种超新生体.

更多相关视频

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

17.9K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.7K

相关实验视频

Last Updated: Jun 30, 2025

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.4K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

17.9K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.7K
  • 治疗策略包括免疫疗法 (皮质类固醇,IVIg,血交换,rituximab,cyclophosphamide) 和症状治疗.
  • 基于抗体配置的综合性诊断方法可以改善患者的治疗结果,并指导治疗决策.